The Pregnabit system will be tested by the Norwegian leader of telemedicine solutions providers. This is the beginning of the commercialization of the company solutions in northern Europe.
Nestmedic has just signed the first cooperation agreement in Scandinavia. As part of it, the Norwegian partner – a telemedicine company Dignio AS Aksjeselskap – will test the Pregnabit device for a mobile KTG study, as well as a platform for presenting and analyzing telekCT records dedicated to the system.
Norway is the fourth country in the world in terms of the amount of funds spent on healts per capita (6.7 thousand USD per person, according to OECD Health Statistics 2017). This is also one of the strategic markets for Nestmedic.
– Nestmedic’s foreign expansion is gaining momentum. We have recently announced cooperation with a partner in Germany, now Norway is starting. It is a country with high spending on telemedicine and – on a European scale – high fertility – says PhD Patrycja Wizińska-Socha, President of the Management Board of Nestmedic.